The group of Hans Spelbrink, theme Mitochondrial diseases, published a paper in Nucleic Acids Research, showing that two factors that are traditionally implicated in mitochondrial DNA replication, namely the mtDNA helicase Twinkle and the mtDNA single-stranded DNA-binding protein mtSSB, play an important role also in mitochondrial RNA metabolism.Publication: link.
Newly synthesized mitochondrial RNA is concentrated in structures juxtaposed to nucleoids, called RNA granules, that have been implicated in mitochondrial RNA processing and ribosome biogenesis. They showed that two classical mtDNA replication factors, the mtDNA helicase Twinkle and single-stranded DNA-binding protein mtSSB, contribute to RNA metabolism in mitochondria and to RNA granule biology. Twinkle colocalizes with both mitochondrial RNA granules and nucleoids, and it can serve as bait to greatly enrich established RNA granule proteins, such as G-rich sequence factor 1, GRSF1. Likewise, mtSSB also is not restricted to the nucleoids, and repression of either mtSSB or Twinkle alters mtRNA metabolism. Short-term Twinkle depletion greatly diminishes RNA granules but does not inhibit RNA synthesis or processing. Either mtSSB or GRSF1 depletion results in RNA processing defects, accumulation of mtRNA breakdown products as well as increased levels of dsRNA and RNA:DNA hybrids. In particular, the processing and degradation defects become more pronounced with both proteins depleted.
These findings suggest that Twinkle is essential for RNA organization in granules, and that mtSSB is involved in the recently proposed GRSF1-mtRNA degradosome pathway, a route suggested to be particularly aimed at degradation of G-quadruplex prone long non-coding mtRNAs.
Related news items
Towards a better understanding of Leigh Syndrome pathology and intervention published in Brain8 December 2021
Melissa van de Wal and colleagues recently published a comprehensive review in the journal Brain on how Ndufs4 knockout mouse models have been used to unravel the pathomechanism of Leigh Syndrome.read more
Khondrion begins study on optimal dosage of new drug10 February 2020
Pharmaceutical company Khondrion, a spin-off from Radboudumc, has taken another important step in the development of its drug sonlicromanol. The first patients have used the drug as part of a phase 2b study, which focuses on determining the optimum dose and efficacy.read more
Stofwisselkracht grant for Daan Panneman and Richard Rodenburg16 January 2020
Daan Panneman & Richard Rodenburg have been awarded a Stofwisselkracht grant for their proposal “CRISPR/Cas9 knock-in complementation in fibroblasts of mitochondrial disease patients”. Together with Omar Tutakhel & Jan Smeitink they will investigate the possibility of using CRISPR/Cas9 knock-in.read more
New mitochondrial DNA maintenance disease uncovered1 October 2019
The group of Hans Spelbrink, theme Mitochondrial diseases, and colleagues, has identified and characterized mutations in the mtDNA maintenance gene SSBP1 in families with optic atrophy and foveopathy. This paper is now online in The Journal of Clinical Investigation.read more
Tweaking the gearbox of mitochondrial complex I1 November 2018
Alfredo Cabrera-Orefice, Ulrich Brandt and colleagues, theme Mitochondrial Diseases, concluded in Nature Communications that the movement of a critical loop of subunit ND3 located at the ubiquinone-binding pocket of respiratory complex I is required to drive proton pumping.read more
Biodegradable nanoreactors demonstrate ROS shielding in human-complex-I-deficient fibroblasts9 July 2018
Researchers of the Radboudumc and colleagues have successfully developed enzyme-loaded polymersomal nanoreactors capable of undergoing cellular integration in a controlled fashion and, subsequently, function as synthetic organelles.read more